Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Povorcitinib in Hidradenitis Suppurativa
NCT03569371Phase 2Completed
- Sponsor
- Incyte
- Start
- Jul 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of povorcitinib in hidradenitis suppurativa (HS), sponsored by Incyte. Started Jul 2018; status: completed.
02
Drugs
povorcitinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT03569371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03569371.